Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
17 December 2024
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
15 November 2024
NXP800 yields neither severe thrombocytopenia, nor any responses.
14 November 2024
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
13 November 2024
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
13 November 2024
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
13 November 2024
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
12 November 2024
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.